MétaCan
Menu
Back to cohort

PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT‐ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D‐VTD): PHASE 3 CASSIOPEIA STUDY

2019· article· en· W2950269753 on OpenAlexaff
Cyrille Hulin, Philippe Moreau, Michel Attal, Karim Belhadj, Lotfi Benboubker, Denis Caillot, Thierry Façon, Laurent Garderet, F. Kuhnowski, A. M. Stoppa, Brigitte Kolb, Mourad Tiab, Pieter Sonneveld, K.‐S. Jie, Matthijs Westerman, Lixia Pei, Tobias Kampfenkel, Carla de Boer, Jessica Vermeulen, N. W. van de Donk

Bibliographic record

VenueHemaSphere · 2019
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsHotel Dieu Hospital
Fundersnot available
KeywordsMedicinePlerixaforMultiple myelomaAutologous stem-cell transplantationInternal medicineDaratumumabTransplantationSurgeryBortezomibOncologyCXCR4

Abstract

fetched live from OpenAlex

Background: High‐dose therapy (HDT) followed by autologous stem‐cell transplantation (ASCT) is the standard of care in transplant‐eligible newly diagnosed multiple myeloma (NDMM). In the phase 3 CASSIOPEIA study, daratumumab + standard‐of‐care regimen VTd (D‐VTd) significantly improved stringent complete response (sCR), complete response or better (≥CR), and minimal residual disease (MRD)‐negative rates and reduced the risk of progression or death versus VTd in NDMM patients who were eligible for transplant. Aims: Here, we assessed stem cell yield and transplantation results among patients receiving D‐VTd versus VTd induction prior to HDT and ASCT in Part 1 of the CASSIOPEIA trial. Methods: In Part 1, transplant‐eligible NDMM patients ages 18–65 years were randomized 1:1 to 4 pre‐transplant induction and 2 post‐transplant consolidation cycles of D‐VTd or VTd alone. After induction, patients underwent stem cell mobilization with cyclophosphamide 3 g/m 2 (recommended dose) and granulocyte colony‐stimulating factor (G‐CSF). Peripheral blood stem cells were harvested based on response to mobilization. Plerixafor was administered if stem cell collection failed at first attempt and in accordance with institutional practice. Melphalan 200 mg/m 2 IV was given as HDT prior to ASCT. Results: A total of 1,085 patients were randomized to D‐VTd (n = 543) or VTd (n = 542). Among patients who completed mobilization (D‐VTd, 506; VTd, 492), more patients in the D‐VTd arm received plerixafor during mobilization than in the VTd arm (21.7% vs 7.9%). Patients underwent a median (range) of 2 (1–6) versus 1 (1–4) days of apheresis for D‐VTd versus VTd. The median number of CD34 + cells collected was lower in patients receiving D‐VTd versus VTd (6.3 × 10 6 /kg vs 8.9 × 10 6 /kg). Nevertheless, a similar percentage of intention‐to‐treat patients receiving D‐VTd versus VTd underwent ASCT (90.1% vs 89.3%). The median number of CD34 + cells transplanted for D‐VTd versus VTd was 3.3 × 10 6 /kg versus 4.3 × 10 6 /kg. Hematopoietic reconstitution rates were high and similar in transplanted patients receiving D‐VTd versus VTd (99.8% vs 99.6%). For D‐VTd versus VTd, a median (range) of 13.0 (6–54) versus 13.0 (4–43) days was required to achieve sustained absolute neutrophil counts >500 cells/mm 3 , and a median (range) of 14.0 (2–56) versus 12.0 (1–47) days was required to achieve sustained platelets >20,000 cells/mm 3 without transfusion. Summary/Conclusion: Stem cell mobilization and collection was feasible with D‐VTd induction. Adding daratumumab to VTd allowed successful transplantation in patients with NDMM who were transplant eligible.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.101
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.292
Teacher spread0.268 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueHemaSphereSame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207